Lv51
820 积分 2020-08-12 加入
Biologics-Induced Immunophenotypic Cross-Switching in Patients with Psoriasis and Atopic Dermatitis
3分钟前
已完结
Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis
14分钟前
已完结
Sequencing of Targeted Therapy in Psoriasis: Does it Matter?
11天前
已完结
Rebuilding the gut ecosystem: Emerging strategies targeting the microbiota in antibiotic-associated diarrhea
25天前
已关闭
Apremilast in people living with HIV with psoriasis vulgaris: A case report
1个月前
已完结
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure
1个月前
已完结
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
1个月前
已完结
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
1个月前
已关闭
The Risk of Cancer in Patients With Psoriasis
1个月前
已完结
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
1个月前
已完结
皖公网安备34019202002308
